Dyne Therapeutics is a clinical-stage biopharmaceutical focused on muscle diseases, notably Duchenne Muscular Dystrophy (DMD), Facioscapulohumeral Muscular Dystrophy (FSHD), and Myotonic Dystrophy Type 1 (DM1). Its lead candidate Zeleciment Rostudirsen has received FDA priority review with a PDUFA date in early 2027, while the company recently initiated a Phase 1 trial for DYNE-302 in FSHD. These regulatory advancements underpin its competitive moat in orphan indications. Despite widening net losses reflecting ongoing R&D investment, Dyne maintains a strong liquidity position, bolstered by a recent $375 million equity offering and expanded debt facility, providing runway into mid-2028. The core challenges remain clinical trial enrollment pace and eventual regulatory approvals needed to validate its platform.